Health ❯ Healthcare ❯ Oncology

Multiple Myeloma

Clinical Trials Smoldering Multiple Myeloma Patient-Reported Outcomes Treatment Regimens Treatment Efficacy Treatment Options Teclistamab and Daratumumab Treatment Strategies Drug Treatments Daratumumab

Single CAR T Infusion Clears Residual Disease in High-Risk Smoldering Myeloma Trial

Early, one-time CAR T shows promise to shift care for high-risk smoldering myeloma pending confirmation in larger trials.

FDA Grants National Priority Voucher to J&J’s Tecvayli–Darzalex Combo in Multiple Myeloma

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

J&J Myeloma Trial Stopped Early After Tecvayli–Darzalex Shows PFS and OS Benefit

Nature Papers Identify RHOG and CDKN1B as In Vivo Boosters for CAR T Cells

USFDA Clears Lupin’s Generic Lenalidomide as Nagpur Site Receives Six Observations

FDA Advisers Recommend Against Approval of GSK’s Myeloma Drug Blenrep

Study Highlights Patient-Reported Physical Function as Key Predictor of Daratumumab Success in Multiple Myeloma